204 related articles for article (PubMed ID: 15699766)
1. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients.
Parrott NR; Hammad AQ; Watson CJ; Lodge JP; Andrews CD
Transplantation; 2005 Feb; 79(3):344-8. PubMed ID: 15699766
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
Ponticelli C; Yussim A; Cambi V; Legendre C; Rizzo G; Salvadori M; Kahn D; Kashi H; Salmela K; Fricke L; Heemann U; Garcia-Martinez J; Lechler R; Prestele H; Girault D;
Transplantation; 2001 Oct; 72(7):1261-7. PubMed ID: 11602853
[TBL] [Abstract][Full Text] [Related]
4. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
[TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine.
Filipponi F; Callea F; Salizzoni M; Grazi GL; Fassati LR; Rossi M; Risaliti A; Burra P; Agnes S; De Carlis L; Valente U; Ferrara R; Pisati R
Transplantation; 2004 Nov; 78(10):1488-95. PubMed ID: 15599313
[TBL] [Abstract][Full Text] [Related]
6. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
Kahan BD; Rajagopalan PR; Hall M
Transplantation; 1999 Jan; 67(2):276-84. PubMed ID: 10075594
[TBL] [Abstract][Full Text] [Related]
7. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
[TBL] [Abstract][Full Text] [Related]
8. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil.
Vincenti F; Monaco A; Grinyo J; Kinkhabwala M; Roza A
Am J Transplant; 2003 Mar; 3(3):306-11. PubMed ID: 12614286
[TBL] [Abstract][Full Text] [Related]
9. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
10. Basiliximab induction in renal transplantation: long-term outcome.
Atlani M; Sharma RK; Gupta A
Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
[TBL] [Abstract][Full Text] [Related]
11. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
Neuhaus P; Clavien PA; Kittur D; Salizzoni M; Rimola A; Abeywickrama K; Ortmann E; Chodoff L; Hall M; Korn A; Nashan B;
Liver Transpl; 2002 Feb; 8(2):132-42. PubMed ID: 11862589
[TBL] [Abstract][Full Text] [Related]
12. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
[TBL] [Abstract][Full Text] [Related]
13. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
Lawen JG; Davies EA; Mourad G; Oppenheimer F; Molina MG; Rostaing L; Wilkinson AH; Mulloy LL; Bourbigot BJ; Prestele H; Korn A; Girault D;
Transplantation; 2003 Jan; 75(1):37-43. PubMed ID: 12544868
[TBL] [Abstract][Full Text] [Related]
14. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
[TBL] [Abstract][Full Text] [Related]
15. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
[TBL] [Abstract][Full Text] [Related]
16. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
17. Induction with basiliximab in renal transplantation.
Ferrer F; Machado S; Alves R; Macário F; Bastos C; Roseiro A; Mota A
Transplant Proc; 2010 Mar; 42(2):467-70. PubMed ID: 20304166
[TBL] [Abstract][Full Text] [Related]
18. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
Clark G; Walsh G; Deshpande P; Koffman G
Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
[TBL] [Abstract][Full Text] [Related]
19. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.
Thistlethwaite JR; Nashan B; Hall M; Chodoff L; Lin TH
Transplantation; 2000 Sep; 70(5):784-90. PubMed ID: 11003358
[TBL] [Abstract][Full Text] [Related]
20. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
